By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

CRISPR Therapeutics 

675 West Kendall Street

Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-580-9212 Fax: n/a


SEARCH JOBS

CRISPR Therapeutics is a leading gene editing company focused on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene editing platform. CRISPR is a revolutionary technology that allows for precise, directed changes to genomic DNA. The Company’s multi-disciplinary team of world-class researchers and drug developers is working on a number of wholly-owned programs to treat serious diseases with high unmet need.

YEAR FOUNDED:

November 2013

LEADERSHIP:

Founders: Rodger Novak, Emmanuelle Charpentier, Shaun Foy

Scientific Founders: Chad Cowan, Daniel Anderson, Stephen Elledge, Craig Mello, Matthew Porteus

CEO and Co-founder: Rodger Novak

CFO: Marc Becker

CSO (Scientific): Sven Ante (Bill) Lundberg

JOBS:

Please click here for CRISPR Therapeutics job opportunities.

FOLLOW CRISPR THERAPEUTICS:






Key Statistics


Email: info@crisprtx.com
Ownership: Public

Web Site: CRISPR
Employees:
Symbol: CRSP
 









Company News
CRISPR (CRSP) Announces Patent For CRISPR/Cas Genome Editing In China 6/19/2017 10:22:48 AM
CRISPR (CRSP) And MaSTherCell Sign Service Agreement For The Development And Manufacturing Of Allogeneic Cell Therapies 6/13/2017 12:35:49 PM
CRISPR (CRSP) Appoints James R. Kasinger As General Counsel 6/7/2017 8:21:53 AM
CRISPR (CRSP) And MaSTherCell Sign Service Agreement For The Development And Manufacturing Of Allogeneic Cell Therapies 6/6/2017 7:29:56 AM
CRISPR (CRSP), Editas Medicine (EDIT) and Intellia Fall as Scientific Paper Warns of Unintended Mutations Linked to Gene-Editing 5/31/2017 6:07:53 AM
CRISPR (CRSP) Announces The Presentation Of Data On Its Lead Program At The Upcoming 22nd European Hematology Association Annual Congress 5/18/2017 10:19:53 AM
CRISPR (CRSP) And Collaborators At The University of Florida Awarded Target ALS Grant To Develop CRISPR/Cas9-Based Approaches For ALS 5/16/2017 10:42:11 AM
CRISPR (CRSP) Reports Financial Results For The Three Months Ended March 31, 2017 And Provides Business Update 5/11/2017 8:54:22 AM
CRISPR (CRSP) Announces Exclusive License Of Lipid Nanoparticle Technologies Developed At MIT 5/8/2017 10:28:56 AM
CRISPR (CRSP) Appoints Samarth Kulkarni, Ph.D. As President, Expanding Role Beyond Chief Business Officer To Oversee U.S. Operations 5/4/2017 10:49:44 AM
1234
//-->